Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging
Line Jee Hartmann Rasmussen, Avshalom Caspi, Antony Ambler, Andrea Danese, Maxwell Elliott, Jesper Eugen-Olsen, Ahmad R Hariri, HonaLee Harrington, Renate Houts, Richie Poulton, Sandhya Ramrakha, Karen Sugden, Benjamin Williams, Terrie E Moffitt, Line Jee Hartmann Rasmussen, Avshalom Caspi, Antony Ambler, Andrea Danese, Maxwell Elliott, Jesper Eugen-Olsen, Ahmad R Hariri, HonaLee Harrington, Renate Houts, Richie Poulton, Sandhya Ramrakha, Karen Sugden, Benjamin Williams, Terrie E Moffitt
Abstract
Background: To understand and measure the association between chronic inflammation, aging, and age-related diseases, broadly applicable standard biomarkers of systemic chronic inflammation are needed. We tested whether elevated blood levels of the emerging chronic inflammation marker soluble urokinase plasminogen activator receptor (suPAR) were associated with accelerated aging, lower functional capacity, and cognitive decline.
Methods: We used data from the Dunedin Study, a population-representative 1972-1973 New Zealand birth cohort (n = 1037) that has observed participants to age 45 years. Plasma suPAR levels were analyzed at ages 38 and 45 years. We performed regression analyses adjusted for sex, smoking, C-reactive protein, and current health conditions.
Results: Of 997 still-living participants, 875 (88%) had plasma suPAR measured at age 45. Elevated suPAR was associated with accelerated pace of biological aging across multiple organ systems, older facial appearance, and with structural signs of older brain age. Moreover, participants with higher suPAR levels had greater decline in physical function and cognitive function from childhood to adulthood compared to those with lower suPAR levels. Finally, improvements in health habits between ages 38 and 45 (smoking cessation or increased physical activity) were associated with less steep increases in suPAR levels over those years.
Conclusions: Our findings provide initial support for the utility of suPAR in studying the role of chronic inflammation in accelerated aging and functional decline.
Keywords: Gait speed; Immunosenescence; Inflammaging; MRI; Pace of aging.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Gerontological Society of America.
Figures
References
- Harper S. Economic and social implications of aging societies. Science. 2014;346:587–591. doi:10.1126/science.1254405
- Burch JB, Augustine AD, Frieden LA, et al. Advances in geroscience: impact on healthspan and chronic disease. J Gerontol A Biol Sci Med Sci. 2014;69(suppl 1):S1–S3. doi:10.1093/gerona/glu041
- Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25:1822–1832. doi:10.1038/s41591-019-0675-0
- Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369. doi:10.1161/01.cir.0000053730.47739.3c
- Desmedt S, Desmedt V, Delanghe JR, Speeckaert R, Speeckaert MM. The intriguing role of soluble urokinase receptor in inflammatory diseases. Crit Rev Clin Lab Sci. 2017;54:117–133. doi:10.1080/10408363.2016.1269310
- Lyngbæk S, Sehestedt T, Marott JL, et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol. 2013;167:781–785. doi:10.1016/j.ijcard.2012.03.040
- Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268:296–308. doi:10.1111/j.1365-2796.2010.02252.x
- Rasmussen LJH, Schultz M, Gaardsting A, et al. Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer. Int J Cancer. 2017;141:191–199. doi:10.1002/ijc.30732
- Haastrup E, Grau K, Eugen-Olsen J, Thorball C, Kessing LV, Ullum H. Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants. PLoS One. 2014;9:e110555. doi:10.1371/journal.pone.0110555
- Haupt TH, Rasmussen LJH, Kallemose T, et al. Healthy lifestyles reduce suPAR and mortality in a Danish general population study. Immun Ageing. 2019;16:1. doi:10.1186/s12979-018-0141-8
- Rasmussen LJ, Ladelund S, Haupt TH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33:769–775. doi:10.1136/emermed-2015-205444
- Persson M, Östling G, Smith G, et al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke. 2014;45:18–23. doi:10.1161/STROKEAHA.113.003305
- Guthoff M, Wagner R, Randrianarisoa E, et al. Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus. Sci Rep. 2017;7:40627. doi:10.1038/srep40627
- Tarpgaard LS, Christensen IJ, Høyer-Hansen G, et al. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. Int J Cancer. 2015;137:2470–2477. doi:10.1002/ijc.29476
- Sorio C, Mafficini A, Furlan F, et al. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer. 2011;11:448. doi:10.1186/1471-2407-11-448
- Hayek SS, Sever S, Ko YA, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373:1916–1925. doi:10.1056/NEJMoa1506362
- Hayek SS, Leaf DE, Samman Tahhan A, et al. Soluble urokinase receptor and acute kidney injury. N Engl J Med. 2020;382(5):416–426. doi:10.1056/NEJMoa1911481.
- Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012;10:2. doi:10.1186/1741-7015-10-2
- Rasmussen LJH, Moffitt TE, Eugen-Olsen J, et al. Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood. J Child Psychol Psychiatry. 2019;60:199–208. doi:10.1111/jcpp.12928
- Rasmussen LJH, Moffitt TE, Arseneault L, et al. Association of adverse experiences and exposure to violence in childhood and adolescence with inflammatory burden in young people. JAMA Pediatr. 2020;174(1):38–47. doi:10.1001/jamapediatrics.2019.3875.
- Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27:157–172. doi:10.3233/DMA-2009-0657
- Dekkers PE, ten Hove T, te Velde AA, van Deventer SJ, van Der Poll T. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun. 2000;68(4):2156–2160. doi:10.1128/IAI.68.4.2156-2160.2000.
- Enocsson H, Wetterö J, Skogh T, Sjöwall C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transl Res. 2013;162:287–296. doi:10.1016/j.trsl.2013.07.003
- Lyngbæk S, Marott JL, Møller DV, et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am J Cardiol. 2012;110:1756–1763. doi:10.1016/j.amjcard.2012.08.008
- Poulton R, Moffitt TE, Silva PA. The Dunedin Multidisciplinary Health and Development Study: overview of the first 40 years, with an eye to the future. Soc Psychiatry Psychiatr Epidemiol. 2015;50:679–693. doi:10.1007/s00127-015-1048-8
- Richmond-Rakerd LS, D’Souza S, Andersen SH, et al. Clustering of health, crime and social-welfare inequality in 4 million citizens from two nations. Nat Hum Behav. 2020;4(3):255–264. doi:10.1038/s41562-019-0810-4.
- Belsky DW, Caspi A, Israel S, Blumenthal JA, Poulton R, Moffitt TE. Cardiorespiratory fitness and cognitive function in midlife: neuroprotection or neuroselection? Ann Neurol. 2015;77:607–617. doi:10.1002/ana.24356
- Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(9 Suppl):S498–S516. doi:10.1097/00005768-200009001-00009
- McClintock MK, Dale W, Laumann EO, Waite L. Empirical redefinition of comprehensive health and well-being in the older adults of the United States. Proc Natl Acad Sci U S A. 2016;113:E3071–E3080. doi:10.1073/pnas.1514968113
- Rasmussen LJH, Caspi A, Ambler A, et al. Association of neurocognitive and physical function with gait speed in midlife. JAMA Netw Open. 2019;2:e1913123. doi:10.1001/jamanetworkopen.2019.13123
- Elliott ML, Belsky DW, Knodt AR, et al. Brain-age in midlife is associated with accelerated biological aging and cognitive decline in a longitudinal birth cohort. Mol Psychiatry. 2019. doi:10.1038/s41380-019-0626-7.
- Belsky DW, Caspi A, Houts R, et al. Quantification of biological aging in young adults. Proc Natl Acad Sci U S A. 2015;112:E4104–E4110. doi:10.1073/pnas.1506264112
- Liem F, Varoquaux G, Kynast J, et al. Predicting brain-age from multimodal imaging data captures cognitive impairment. Neuroimage. 2017;148:179–188. doi:10.1016/j.neuroimage.2016.11.005
- The RAND Corporation. RAND 36-Item Short Form Survey (SF-36) . Accessed July 22, 2020.
- Bohannon RW, Larkin PA, Cook AC, Gear J, Singer J. Decrease in timed balance test scores with aging. Phys Ther. 1984;64(7):1067–1070. doi:10.1093/ptj/64.7.1067.
- Vereeck L, Wuyts F, Truijen S, Van de Heyning P. Clinical assessment of balance: normative data, and gender and age effects. Int J Audiol. 2008;47:67–75. doi:10.1080/14992020701689688
- Springer BA, Marin R, Cyhan T, Roberts H, Gill NW. Normative values for the unipedal stance test with eyes open and closed. J Geriatr Phys Ther. 2007;30:8–15. doi:10.1519/00139143-200704000-00003
- Rantanen T, Guralnik JM, Foley D, et al. Midlife hand grip strength as a predictor of old age disability. JAMA. 1999;281:558–560. doi:10.1001/jama.281.6.558
- Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil. 1985;66:69–74.
- Jones CJ, Rikli RE. Measuring functional fitness of older adults. J Act Aging. 2002;(March-April):24–30.
- Rikli RE, Jones CJ. Functional fitness normative scores for community-residing older adults, ages 60–94. J Aging Phys Act. 1999;7(2):162–181. doi:10.1123/japa.7.2.162.
- Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999;70:113–119. doi:10.1080/02701367.1999.10608028
- Wechsler D. Wechsler Adult Intelligence Scale. 4th ed. San Antonio, TX: Pearson Assessment; 2008.
- Eugen-Olsen J, Ladelund S, Sørensen LT. Plasma suPAR is lowered by smoking cessation: a randomized controlled study. Eur J Clin Invest. 2016;46:305–311. doi:10.1111/eci.12593
- Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14:877–882. doi:10.1016/j.jamda.2013.05.009
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194–1217. doi:10.1016/j.cell.2013.05.039
- Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–9. doi:10.1093/gerona/glu057.
- Walker KA, Walston J, Gottesman RF, Kucharska-Newton A, Palta P, Windham BG. Midlife systemic inflammation is associated with frailty in later life: the ARIC study. J Gerontol A Biol Sci Med Sci. 2019;74:343–349. doi:10.1093/gerona/gly045
- Pawelec G. Age and immunity: what is “immunosenescence”? Exp Gerontol. 2018;105:4–9. doi:10.1016/j.exger.2017.10.024
- Parker D, Sloane R, Pieper CF, et al. Age-related adverse inflammatory and metabolic changes begin early in adulthood. J Gerontol A Biol Sci Med Sci. 2019;74:283–289. doi:10.1093/gerona/gly121
- Piber D, Olmstead R, Cho JH, et al. Inflammaging: age and systemic, cellular, and nuclear inflammatory biology in older adults. J Gerontol A Biol Sci Med Sci. 2019;74:1716–1724. doi:10.1093/gerona/glz130
- Lu Y, Monaco G, Camous X, et al. Biomarker signatures predicting 10-year all-cause and disease-specific mortality. J Gerontol A Biol Sci Med Sci. 2019;74:469–479. doi:10.1093/gerona/gly138
- Alpert A, Pickman Y, Leipold M, et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat Med. 2019;25:487–495. doi:10.1038/s41591-019-0381-y
- Törnkvist PBS, Haupt TH, Rasmussen LJH, et al. Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality. Br J Nutr. 2019;121:699–708. doi:10.1017/S0007114518003720
Source: PubMed